Summary Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). 
The concept of targeting drugs on to malignant cells proposed by Ehrlich (1900) offers a potential improvement over one of the major limitations of cancer chemotherapy, viz. the limited selectivity of drugs for cancer cells. The use of antibodies as carriers was tested experimentally in an L1210 leukaemia (Mathe et al., 1958) and clinically in malignant melanoma (Ghose et al., 1972) .
Despite reports of some success with this approach it has not been widely adopted. This has been partly due to the inability to demonstrate tumour-specific antigens as targets in human tumours; however, in order to increase the therapeutic index of a drug, differential expression of the target by the tumour compared to normal tissue may be sufficient. The well characterised tumour-associated antigens, carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP), offer such potential targets in man. Another reason for caution with this approach has been scepticism about the in vivo stability of the drug and antibody conjugate. It was demonstrated in the mouse EL4 lymphoma model, that drug and antibody were interactive and more effective than a conjugate of the two (Davies & O'Neill, 1973) . This led to a pilot study of drug and antibody interaction in patients with resected bronchogenic carcinoma 0007-0920/83/010035-08 $01.00 (Newman et al., 1977) and to studies of a variety of drug and antibody conjugates and intermediate carriers (Ghose & Blair, 1978; Lee & Hwang, 1979; Dullens & De Weger, 1980, and Rowland, 1982) .
The demonstration of enhanced toxicity of vincristine for a CEA-secreting lung cancer cell line in the presence of anti-CEA-immunoglobulin (Ig) (Johnson et al., 1980) encouraged us to investigate direct conjugation of vinca alkaloids to antibody. The toxicity of vindesine for a CEA-secreting cell line was found to be greatly increased when conjugated to an anti-CEA-Ig (Johnson et al., 1981) . The aims of the present study were to investigate the ability to localise and safety of administration of this conjugate in patients with advanced metastatic adenocarcinomas refractory to established forms of treatment.
Materials and methods Patients
Eight patients with advanced metastatic carcinoma refractory to previous treatment were entered into this study; all gave informed consent. Patients selected had tumour types likely to express CEA and to localise anti-CEA-antibodies (Goldenberg et al., 1978a; Dykes et al., 1980; Van Nagell et al., 1980) . Four had disseminated ovarian carcinomas and 4 had disseminated colorectal carcinomas. Before injection of radio-labelled antibody, patients were tested for immediate and delayed hypersensitivity to sheep Ig (0.1 ml of mg ml-1 (Dykes et al., 1980) . In our hands it localised on sections of a formalin-fixed CEA-secreting colonic carcinoma in an indirect immunoperoxidase test at a titre of 1/80,000. However, in the immunocytochemical tests there was still residual antibody activity to shared NCA determinants as demonstrated by staining of chronic myeloid leukaemia cells and splenic myeloid cells (Ford et al., 1981) .
Conjugate Vindesine (VDS)-anti-CEA Ig conjugates were prepared at Lilly Research Centre Ltd. from desacetylvincaleucoblastine acid hydrazide under aseptic conditions by a modification of the procedure described for vindesine-BSA (Conrad et al., 1979) and purified by gel filtration. Four batches were prepared with initial conjugation ratios of 4.1, 5.4, 4.3 and 11 moles vindesine per mole IgG. An iodinated aliquot of Batch I was used to scan patients 1 and 2. Iodinated Batch II was used to scan patients 3-6. Patients 7 and 8 were scanned with an iodinated aliquot of the sheep anti-CEA Ig used to prepare Batch IV.
For assessment of safety, patients received doses of 1.2-42mg conjugate, containing 24-1800pg VDS, injected i.v. in 100ml of 1% human serum albumin in saline (HSA-saline) over a 30-60min period. All conjugates were 0.22pm filtered before dilution in sterile, HSA-saline.
Radiolabelling of conjugate/antibody Aliquots of batches of conjugate (or antibody) were iodinated with 1311 using a modified chloramine-T method (Garvey et al., 1977) . Free iodine was removed on a Sephadex G-25 column which was eluted with HSA-saline. Fractions containing the protein peak as determined by y-counting were pooled and sterile filtered through a 0.22,pm filter.
Radiolabelled conjugate (or antibody) was injected i.v. in 100ml of sterile HSA-saline over a 30-60min period.
All solutions were tested for pyrogenicity and sterility. lodinated conjugates were tested at 6pgIgkg-1 body weight in rabbits and uniodinated conjugates were tested from 45-198 pg Ig kg-1 body weight depending on the dose to be administered to patients. All batches were negative.
Photoscanning
Between 230-520pgIg conjugate (6-14 pg of VDS) containing 541-1014pCi protein bound 131I was administered to patients 1-6. Patients 7 and 8 each received 471 pg of unconjugated Ig containing 1056 pCi 1311.
Each patient received i.v. 99mTc-pertechnetate (500 pCi) 30 min before each scan, and 99mTc-labelled human serum albumin (500 pCi) 5 min before each scan. These distribute similarly to free iodide and radiolabelled antibody respectively in the blood pool. Images of the chest and abdomen were obtained with a gamma camera (Searle LFOV with medium energy collimator) initially at 4, 24 and 48 h after injection of iodinated material. The 4 h scans were discontinued for patients 3-8. The camera was linked to a DEC PDP1 1/40 computer with a dual isotope facility and a colour scale visual display unit. The data were stored and displayed in a 64 x 64 matrix. After normalising over the cardiac area, subtraction of the technetium component from the iodine component was performed to visualise areas of selective uptake of conjugate.
Measurement of anti-CEA activity A modified enzyme-linked immunosorbent assay (ELISA) (Woodhouse et al., 1982) was used to measure anti-CEA activity of antibody, conjugate and iodinated conjugate. Briefly, disposable cuvettes were coated with purified CEA, washed, blocked by incubation with BSA, washed and the test sample added, before incubation at 35°C for 3 h. Following a further washing, rabbit anti-sheep IgG horseradish peroxidase conjugate (Nordic, U.K.) was added. The cuvettes were incubated at 35°C for 3 h, washed and then ABTS (2.2-azino-di-(3-ethylbenzthiazoline sulphonic acid) (Sigma)) was added. Absorbance at 405 nm was measured using a Gilford PR-50 processor-reader.
Measurement of serum CEA levels CEA measurements were performed by Dr. P. Gosling, East Birmingham Hospital, using a modified double antibody technique (Booth et al., 1973) . Serum samples were perchloric acid-extracted before assay.
Results
The dosages of radiolabelled conjugate/antibody and uniodinated conjugate received by each patient are given in Table I .
Details of the patients in this study and the scanning results are summarised in Table II. Patients 1-6 received radiolabelled conjugate, followed within 4-54 days by unlabelled conjugate. Localisation of radioactivity which equated with clinically detectable disease was seen in patients 1, 2, 3, 4 & 6. The localisation picture for patient 5 was equivocal. Figures 1 and 2 illustrate localisation images. Figure 1 is the 48h subtraction scan for patient 2 who had a large abdomino-pelvic mass which was confirmed on CT scans. Localisation of isotope occurred in the mass and in the right kidney. Subsequent investigation of this patient by intravenous pyelography indicated a right hydronephrosis due to compression of the right ureter by the tumour. Impaired excretion apparently resulted in an accumulation of isotope in the right kidney. Figure 2 is the 48 h subtraction scan for patient 6 who had an extensive pelvic tumour mass and central palpable abdominal masses. Ultrasound examination confirmed the presence of enlarged para-aortic and coeliac axis nodes. Localisation of isotope coinciding with these, and the pelvic mass at the primary site, can be seen in Figure 2 .
For practical reasons, the last 2 patients received uniodinated conjugate and then radiolabelled unconjugated antibody. There was no evidence of localisation in these patients (see Discussion).
The relative anti-CEA activities of the noniodinated conjugates in ELISA compared to the original antibody, when tested within 14 days of conjugation, were: Batch I, 98%; Batch II, 100%; Batch III, 80%. In the case of Batch IV it was not possible to obtain a relative anti-CEA value. After iodination the values were: Batch I, 48%; Batch II, 72%. Batches III and IV were not iodinated and the radiolabelled antibody used for patients 7 and 8 had 70% activity.
With the exception of patient 6, all had raised (>15 ngml-1) pretreatment serum CEA levels ( Table 2) . We noted no significant decline in CEA levels in any of the patients after the radiolocalising dose. One day after administration of 11.06mg VDS-Ig conjugate to patient 3, there was a fall from 31-17ngml-' which was sustained for 3 days. Similarly, for patient 6, who developed a raised CEA level of 37ngml-1 from a pre-treatment value Idose given was within this estimated range-see Discussion. of 13 ng ml-1, one day after receiving 33.4mg VDSIg conjugate this level fell to 22ngml-'. Five days later the CEA level began to increase. In the other patients no change was observed. None of the patients had immediate or delayed hypersensitivity reactions to normal sheep Ig, either before the first or second dose of conjugate, nor any reaction to the conjugate. The period between conjugation and administration of the localising dose was 6-20 days; between conjugation and administration of escalated dose was 3-25 days, and the time between localising and escalated doses was 4-54 days. Patients 7 and 8 received unconjugated antibody 8 and 6 days respectively before they received conjugate.
In none of the 8 patients was there any toxicity or derangement of biochemical, renal or liver function which had not been present at entry into the investigation and which could be attributed to the administration of conjugate. Liver function became increasingly abnormal during follow-up in patient 3. Patient 6 developed obstructive jaundice and deranged liver function between the first and second administration of conjugate which was due to enlarged metastatic lymph nodes in the porta hepatis and para-aortic areas. Progressive gastrointestinal obstruction was noted in patients 1 and 3 and was attributable to neoplastic adhesions which were confirmed at laparotomy for patient 1. Progressive pelvic recurrence was noted in patient 5 during the study. Five of the patients were anaemic (3, 4, 5, 7 and 8) and only in the last patient was this progressive. Two patients (4 and 8) also had a short-lived thrombocytosis. In no case was the abnormal renal function in patients 1, 3, 4 and 5 further impaired by administration of conjugate. Also, the cis-platinum-related peripheral sensory neuropathy in patient 4 apparently improved during the investigation.
Three days after receiving radiolabelled conjugate patient 1 underwent sigmoidoscopy and biopsies of tumour and normal rectal tissue were obtained. These were weighed and the radioactivity measured in a y-counter. The ratio of normal:tumour (N:T) counts was 1:1.2. The tissues were then macerated with a scalpel blade, weighed, washed 3 x with RPMI 1640 and the counts remeasured. The N:T ratio was 1:4.6. One week after receiving radiolabelled conjugate this patient had a laparotomy and was found to have numerous adhesions and liver secondaries. A colostomy was performed and biopsies taken of "normal" and metastatic hepatic tissue. Following the same procedure as before the N:T ratio was 1:0.6.
Discussion
One of the aims of this study was to determine whether radio-localisation of "3'1-labelled VDSanti-CEA could be achieved in human tumours. This was clearly demonstrated in 4/8 patients (2, 3, 4 & 6). Overall, the scanning results for Patient 1 were also consistent with localisation. However, the uniform uptake in the liver at 4 h may have been due to liver secondaries, or, alternatively, to deposition of anti-CEA/CEA immune complexes (pre-treatment CEA level of >3,550ngml-1). The latter possibility is strengthened by the N:T ratio of radioactivity in the liver of 1:0.6 (Dykes et al., 1980) . However, we favour the third possibility which is that the CEA binding sites had been saturated by the administration of conjugate prior to receiving the radiolocalising dose. Both patients received up to 42mg of conjugated Ig 8 and 6 days respectively before their radiolocalising dose (Table 1) .
Our results suggest that drug conjugation has destroyed neither the activity of the anti-CEA antibody in vitro, nor its ability to localise in vivo. Most of the antibody activity was retained after conjugation as demonstrated by ELISA and the doses of conjugate required for localisation were similar to doses of unconjugated antibody reported by others (Goldenberg et al., 1978a; Dykes et al., 1980; Mach et al., 1980) . Furthermore, there was an N:T radioactivity ratio of 1:4.6 at 3 days in a biopsy of the colonic tumour from patient 1.
There was no obvious toxicity or hypersensitivity attributable to administration of either radiolocalising or escalated doses of conjugate in any of the eight patients. There were abnormalities, e.g. in liver function, during the course of the study, but none could be directly attributed to the conjugate. Most could be explained by the fact that the patients had advanced disease and had previously undertaken several different treatment programmes. The maximum dose of conjugated drug we administered was 0.9-1.8 mg on a single occasion, which is less than the conventional therapeutic dose of vindesine of 3-4 mg m 2 every 1-4-5mgm-' every 2 weeks (Valdivieso et al., 1981b) .
However, since the conjugate had been shown to be -% 25 times as potent as free VDS against lung cancer cells in vitro (Johnson et al., 1981; Rowland et al., 1982a) , we felt justified in taking a cautious approach when investigating it in patients.
Overall there was no significant decrease in circulating CEA levels due to the administration of either dose of conjugate. Whilst Patients 3 and 6 did show decreases (31-17ngml-1 and 37-22ngml-1 respectively), fluctuations similar to these were noted at other times and did not appear to be treatment related.
Whilst we have clearly demonstrated the feasibility of this approach a number of problems were noted. The most important was aggregation of Batches III and IV, forcing us to change our plan of investigation. For Batch III 80% relative anti-CEA activity was used to calculate the amount of conjugate given. However, for Batch IV it was not possible to do this. We estimate the dose given was within the 5O-100% range. The reason for aggregation remains unexplained at present. A possible factor may have been the higher conjugation ratio of 11:1 achieved with Batch IV. A single batch of conjugate was not used for the entire study in order to minimise the time between conjugation and administration of both radiolocalising and escalated doses, since a loss of anti-CEA activity of the conjugate had been noted in vitro after storage at 4°C for more than 31 days (Johnson et al., 1981) . The longest period between conjugation and administration of conjugate in the present study was 25 days.
CEA was chosen as a model for this investigation because, by immunocytochemistry, it has been shown to be expressed by 62% of colonic carcinomas (Goldenberg et al., 1978b) , 62% of gastric carcinomas (Lee et al., 1978) , 63% of invasive cancers of the cervix (Van Nagell et al., 1979) , and 82% of lung cancers (Ford et al., 1981) .
Also, 100% of primary and 67% of metastatic ovarian carcinoma sites have been shown to localise anti-CEA antibodies in vivo (Van Nagell et al., 1980) and successes have been achieved with other tumours (Goldenberg et al., 1978a; Dykes et al., 1980; Mach et al., 1980) , although, as in this study, not all tumour sites in a patient and not all patients have shown localisation. CEA, therefore, is a potential target applicable to a variety of human cancers.
Vindesine is active in small cell anaplastic carcinoma of the lung (Osterlind et al., 1981) , colorectal (Valdivieso et al., 1981a) and breast carcinomas (Yap et al., 1981; Cobleigh et al., 1981) . Since it is feasible to make conjugates of vindesine with antibody, VDS-anti-CEA conjugates are candidates for clinical evaluation of possible therapeutic effect. Questions that also require resolution and which are the subject of investigation are whether the conjugate is stable in vivo and whether administration of conjugate actually results in increased tissue levels of drug in the target tissue. We are exploring this potential further in vitro and in vivo using polyclonal and monoclonal VDS-antibody conjugates (Rowland et al., 1982ab) . Clinical use of monoclonal conjugates should be acceptable in view of the reports of successful administration of monoclonal antibodies to patients (Nadler et al., 1980; Miller & Levy, 1981) .
